Recent progress of cyclin-dependent kinase inhibitors as potential anticancer agents

Related Experiment Video

Updated: Mar 13, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.9K

Tinghan Li1,2, Tianwei Weng1,2, Minzan Zuo1,2

  • 1Jiangsu Key Laboratory of Drug Design & Optimization, China Pharmaceutical University, Nanjing, 210009, China.

Future Medicinal Chemistry
|October 25, 2016
PubMed

Insights

Targeting cell cycle regulators like cyclin-dependent kinases (CDKs) is crucial for cancer treatment. This review highlights recent advances in CDK inhibitors, focusing on selective compounds for improved cancer chemotherapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Medicinal Chemistry

Background:

  • Cell cycle deregulation is a hallmark of human cancers.
  • Cyclin-dependent kinases (CDKs) are critical regulators of the cell cycle and key targets in cancer therapy.

Purpose of the Study:

  • To review recent advancements in the development of cyclin-dependent kinase (CDK) inhibitors over the past five years.
  • To analyze the design, structural optimization, and structure-activity relationships of small molecule CDK inhibitors.
  • To highlight key interactions between inhibitors and CDK amino acid residues.

Main Methods:

  • Literature review focusing on CDK inhibitors developed in the last 5 years.
  • Analysis of small molecule design rationale and structural modifications.
  • Examination of structure-activity relationships (SAR) and key binding interactions.

Main Results:

  • Summary of broad-range and selective CDK inhibitors.
  • Detailed discussion of design strategies and SAR for prominent compounds.
  • Identification of critical amino acid interactions for inhibitor efficacy.

Conclusions:

  • The development of highly selective CDK inhibitors is a key future direction.
  • Further understanding of gene control mechanisms is essential.
  • Predictive biomarker research will enhance the clinical application of CDK inhibitors.
Keywords:
cancer therapycell cycleclinical trialscyclin-dependent kinasessmall-molecule inhibitorsstructure–activity relationships

More Related Videos

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

19.4K
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.6K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.6K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.7K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
7.0K
Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
136.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K